Sandoz Inc.'s acquisition of Sabex 2002 Inc. , [See Deal], a Canadian maker of injectable generics, gets it into one of the faster growing and more profitable segments of generics. The $565 million cash price tag was steep for a company with $90 million in revenues. But the six-times sales multiple wasn't out of line with the $3.3 billion Teva Pharmaceutical Industries Ltd. paid for Sicor Inc. , the largest generics injectables manufacturer, late last year. [See Deal]
With Teva, its biggest competitor in injectables breathing down its back, Sandoz, a subsidiary of Novartis AG , not...